Современные подходы к ведению детей с муковисцидозом

Проблема своевременной диагностики и правильного ведения пациентов с муковисцидозом актуальна не только в нашей стране, но и во всем мире. Экспертами Союза педиатров России с современных позиций рассмотрены проблемы этиологии, патогенеза, эпидемиологии, диагностики и лечения этого генетического заболевания. Особое внимание уделено методам скрининга для раннего выявления муковисцидоза. Обоснованы принципы комплексной терапии, в том числе рационального использования антибактериальных, муколитических препаратов и ферментозаместительной терапии, во многом определяющие прогноз болезни.

1. Муковисцидоз / под ред. Н.И. Капранова, Н.Ю. Каширской. — М.: МЕДПРАКТИКА-М; 2014. — 672 с.

2. Национальный консенсус «Муковисцидоз: определение, диагностические критерии, терапия» / под ред. Е.И. Кондратьевой, Н.Ю. Каширской, Н.И. Капранова. — М.: ООО «Компания БОРГЕС»; 2016. — 205 с. Доступно по: https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf. Ссылка активна на 17.04.2022.

3. De Boeck K. Cystic fibrosis in the year 2020: disease with a new face. Acta Paediatr. 2020;109(5):893-899. doi: https://doi.org/10.1111/apa.15155

4. Lopes-Pacheco M. CFTR modulators: Shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016;7:275. doi: https://doi.org/10.3389/fphar.2016.00275

5. Регистр больных муковисцидозом в Российской Федерации. 2019 год / под ред. А.Ю. Воронковой, Е.Л. Амелиной, Н.Ю. Каширской и др. — М.: ИД «МЕДПРАКТИКА-М»; 2021. — 68 с. Доступно по: https://mukoviscidoz.org/doc/registr/10472_block_Registre_2017%20site.pdf. Ссылка активна на 17.04.2022.

6. Mogayzel PJ, Naureckas ET, Robinson KA. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med. 2013;187(7):680-689. doi: https://doi.org/10.1164/rccm.201207-1160oe

7. Шагинян И.А., Капранов Н.И., Чернуха М.Ю. и др. Микробный пейзаж нижних дыхательных путей у различных возрастных групп детей, больных муковисцидозом // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2010. — № 1. — С. 15-20.

8. Чернуха М.Ю., Шагинян И.А., Капранов Н.И. и др. Персистенция Burkholderia cepacia у больных муковисцидозом // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2012. — № 4. — С. 93-98.

9. Demco CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol. 1998;25(5):304-308. doi: https://doi.org/10.1002/(sici)1099-0496(199805)25:5<304::aid-ppul3>3.0.co;2-i

10. Аветисян Л.Р., Медведева О.С., Чернуха М.Ю. и др. Эпидемиологические и микробиологические особенности хронической инфекции легких у больных муковисцидозом вызванной Staphylococcus aureus // Педиатрия. Журнал им. Г.Н. Сперанского. — 2020. — Т. 99. — № 2. — С. 102-111. — doi: https://doi.org/10.24110/0031-403X-2020-99-2-102-111

11. Сиянова Е.А., Чернуха М.Ю., Аветисян Л.Р. и др. Мониторинг хронической инфекции легких у больных муковисцидозом, вызванной бактериями Pseudomonas aeruginosa // Педиатрия. Журнал им. Г.Н. Сперанского. — 2018. — Т. 97. — № 2. — C. 77-86. doi: https://doi.org/10.24110/0031-403X-2018-97-2-77-86

12. Liu JC, Modha DE, Gaillard EA. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros. 2013;12(3);187-193. doi: https://doi.org/10.1016/j.jcf.2013.02.003

13. Aaron SD, Vandemheen KL, Freitag A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One. 2012;7(4):e36077. doi: https://doi.org/10.1371/journal.pone.0036077

14. Eickmeier O, Hector A, Singh A, Hart D. Fungi in Cystic Fibrosis: Recent Findings and Unresolved Questions. Curr Fungal Infect Rep. 2015;9:1-5. doi: https://doi.org/10.1007/s12281-014-0211-0

15. Климко Н.Н. Микозы: диагностика и лечение: руководство для врачей. — 3-е изд., перераб. и доп. — М.: Фармтек; 2017. — 272 с.

16. Pinet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis — a review. Med Mycol. 2009;47(4):387-397. doi: https://doi.org/10.1080/13693780802609604

17. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45-68. doi: https://doi.org/10.1183/13993003.00583-2015

18. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270-277. doi: https://doi.org/10.1136/thoraxjnl-2014-206291

19. Burke MS, Ragi JM, Karamanoukian HL, et al. New strategies in thenon-operative management of meconium ileus. J Pediat Surg. 2002;37(5):760-764. doi: https://doi.org/10.1053/jpsu.2002.32272

20. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-178. doi: https://doi.org/10.1016/j.jcf.2018.02.006

21. Кондратьева Е.И., Шерман В.Д., Амелина Е.Л. и др. Клинико-генетическая характеристика и исходы мекониевого илеуса при муковисцидозе // Российский вестник перинаталогии и педиатрии. — 2016. — Т. 61. — № 6. — С. 77-81. — doi: https://doi.org/10.21508/1027-4065-2016-6-77-81

22. Debray D, Narkewicz MR, Bodewes FA, et al. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65(4):443-448. doi: https://doi.org/10.1097/MPG.0000000000001676

23. Ciuca IM, Pop L, Tamaj L, et al. Cystic fibrosis liver disease-from diagnosis to risk factors. Rom J Morphol Embryol. 2014;55(1):91-95.

24. Klotter V, Gunchick C, Siemers E, et al. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One. 2017;12(6):e0178784. doi: https://doi.org/10.1371/journal.pone.0178784

25. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10(Suppl 2):86-102. doi: https://doi.org/10.1016/S1569-1993(11)60014-3

26. Terliesner N, Vogel M, Steighardt A, et al. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. J Pediatr Endocrinol Metab. 2017;30(8):815-821. doi: https://doi.org/10.1515/jpem-2017-0005

27. Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax. 2001;56(8):649-655. doi: https://doi.org/10.1136/thorax.56.8.649

28. Амелина Е.Л., Красовский С.А., Шугинин И.О. Муковисцидоз и беременность: клинико-генетические, функциональные и микробиологические характеристики пациенток // Педиатрия. Журнал им. Г.Н. Сперанского. — 2014. — Т. 93. — № 4. — С. 38-43.

29. King SL, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: AF508 mutation is an independent risk factor. Eur Respir J. 2005;25(1):54-61. doi: https://doi.org/10.1183/09031936.04.00050204

30. Симанова Т.В. Клинико-генетические особенности и костный метаболизм у больных муковисцидозом: автореф дис. ... канд. мед. наук. — М.; 2009. — 28 с.

31. Красовский С.А. Остеопороз у взрослых больных муковисцидозом: автореф. дис. ... канд. мед. наук. — М.; 2012.

32. Горинова Ю.В. Остеопения при хронических болезнях легких у детей: автореф. дис. . канд. мед. наук. — М., 2005.

33. Соболенкова В.С. Системный анализ в ранней диагностике и лечении остеопенического синдрома при муковисцидозе: автореф. дис. . канд. мед. наук. Тула; 2009.

34. Aris RM, Merkel PA, Bachrach LK, et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888-1896. doi: https://doi.org/10.1210/jc.2004-1629

35. Капустина Т.Ю., Капранов Н.И. Состояние минеральной плотности костной ткани у пациентов с муковисцидозом // Педиатрия. Журнал им. Г.Н. Сперанского. — 2008. — Т. 87. — № 5. — С. 36-41.

36. Smyth AR, Bell SC, Bojcin S, et al. Flume European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibrosis. 2014;13(Suppl 1):S23-S42. doi: https://doi.org/10.1016/j.jcf.2014.03.010

37. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis — state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl 3):S225-S264. doi: https://doi.org/10.1086/376525

38. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest. 1999;116(3):639-646. doi: https://doi.org/10.1378/chest.116.3.639

39. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Eur Respir J. 2000;16(3):464-471. doi: https://doi.org/10.1034/j.1399-3003.2000.016003464.x

40. Zolin A, Orenti A, van Rens J., Et al. ECFS Patient Registry. Annual Data Report (2017 data). Version 1.2019. Available online: https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf. Accessed on April 17, 2022.

41. Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. J Cyst Fibros. 2017;16(Suppl 2):S50-S61. doi: https://doi.org/10.1016/j.jcf.2017.07.002

42. Pseudo-Bartter's syndrome. In: Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital; 2020. 8th ed. pp. 173-174. Available online: https://www.rbht.nhs.uk/sites/nhs/files/Cystic%20fibrosis%20guidelines/CF%20G%202020/CF%20guideline%202020%20FINAL_edited.pdf. Accessed on April 17, 2022.

43. Mayer-Hamblett N, Kloster M, Ramsey BW, et al. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials. 2013;34(2):232-238. doi: https://doi.org/10.1016/j.cct.2012.11.005

44. Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol. 2007;61(1):11-17. doi: https://doi.org/10.1016/j.ejrad.2006.11.008

45. Williams SM, Goodman R, Thomson A, et al. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol. 2002;57(5):365-370. doi: https://doi.org/10.1053/crad.2001.0861

46. Mueller-Abt PR, Frawley KJ, Greer RM, et al. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J Cyst Fibros. 2008;7(3):215-221. doi: https://doi.org/10.1016/j.jcf.2007.08.001

47. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(Suppl 1):S100-S107. doi: https://doi.org/10.1016/j.jhep.2004.11.015

48. Brunt ME. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology. 2000;31(1):241-246. doi: https://doi.org/10.1002/hep.510310136

49. Moran A, Brunzell C, Cohen RC. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-2708. doi: https://doi.org/10.2337/dc10-1768

50. Gordon CM, Leonard MB, Zemel BS. 2013 Pediatric Position Development Conference: Executive Summary and Reflections. J Clin Densitom. 2014;17(2):219-224. doi: https://doi.org/10.1016/j.jocd.2014.01.007

51. Southern KW, Merelle MM, Dankert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. 2009;2009(1):CD001402. doi: https://doi.org/10.1002/14651858.CD001402.pub2

52. Шерман В.Д., Кондратьева Е.И., Воронкова А.Ю. и др. Влияние неонатального скрининга на течение муковисцидоза на примере группы пациентов Московского региона // Медицинский Совет. — 2017. — № 18. — С. 124-128. doi: https://doi.org/10.21518/2079-701X-2017-18-124-128

53. Шерман В.Д., Капранов Н.И., Каширская Н.Ю., Кондратьева Е.И. Роль неонатального скрининга в оптимизации медицинской помощи больным муковисцидозом в РФ // Медицинская генетика. — 2013. — Т. 12. — № 11. — С. 24-29.

54. Farrell PM, Rosenstein BJ, White TB, et al. Cystic fibrosis foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):4-14. doi: https://doi.org/10.1016/j.jpeds.2008.05.005

55. Collie JT, Massie RJ, Jones OA, et al. Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis. Pediatr Pulmonol. 2014;49(2):106-117. doi: https://doi.org/10.1002/ppul.22945

56. Mattar ACV, Leone C, Rodrigues JC, Adde FV. Sweat conductivity: an accurate diagnostic test for cystic fibrosis? J Cyst Fibros. 2014;13(5):528-533. doi: https://doi.org/10.1016/j.jcf.2014.01.002

57. Hug MJ, Tummler B. Intestinal current measurements to diagnose cystic fibrosis. J Cyst Fibros. 2004;3(Suppl 2):157-158. doi: https://doi.org/10.1016/j.jcf.2004.05.033

58. Sosnay PR, White TB, Farrell PM, et al. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr. 2017;181S:S52-S57.e7. doi: http://doi.org/10.1016/j.jpeds.2016.09.068

59. Cystic Fibrosis Mutation Database. Available online: http://www.genet.sickkids.on.ca. Accessed on April 17, 2022.

60. Richards S, Aziz N, Bale S, et al. Rehm, the ACMG Laboratory Quality Assurance Committee Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi: http://doi.org/10.1038/gim.2015.30

61. Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35(3):557-577. doi: http://doi.org/10.1016/j.clnu.2016.03.004

62. Cystic fibrosis: diagnosis and management NICE guideline. National Institute for Health and Care Excellence; 2017. Available online: https://www.nice.org.uk/guidance/ng78/resources/cystic-fibrosis-diagnosis-and-management-pdf-1837640946373. Accessed on April 17, 2022.

63. Goss CH, Mayer-Hamblett N, Kronmal RA, et al. Laboratory parameter profiles among patients with cystic fibrosis. J Cyst Fibros. 2007;6(2):117-123. doi: http://doi.org/10.1016/j.jcf.2006.05.012

64. Nazareth D, Walshaw M. A review of renal disease in cystic fibrosis. J Cyst Fibros. 2013;12(4):309-317. doi: http://doi.org/10.1016/j.jcf.2013.03.005

65. Public Health England. Identification of Pseudomonas species and other NonGlucose Fermenters. UK Standards for Microbiology Investigations. 2015. ID 17. Issue 3. 41 p. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/422699/ID_17i3.pdf. Accessed on April 17, 2022.

66. H0iby N, Ciofu O, Bjarnsholt T. Pseudomonas. In: Pfaller MA, Richter SS, Funke G, et al. Manual of Clinical Microbiology. 11th ed. ASM Press; 2015. p. 774. doi: https://doi.org/10.1128/9781555817381.ch42

67. Определение чувствительности микроорганизмов к антимикробным препаратам: клинические рекомендации. — Межрегиональная ассоциация по клинической микробиологии и антимикробной терапии; 2021. Доступно по: https://www.antibiotic.ru/files/321/clrec-dsma2018.pdf. Ссылка активна на 17.04.2022.

68. Patterson TF. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi: https://doi.org/10.1093/cid/ciw326

69. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-e38. doi: https://doi.org/10.1016/j.cmi.2018.01.002

70. Chaaban MR, Kejner A, Rowe SM, Woodworth BA. Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allerg. 2013;27(5):387-395. doi: https://doi.org/10.2500/ajra.2013.27.3919

71. Roby BB, McNamara J, Finkelstein M, Sidman J. Sinus surgery in cystic fibrosis patients: Comparison of sinus and lower airway cultures. Int J Pediatr Otorhinolaryngol. 2008;72(9):1365-1369. doi: https://doi.org/10.1016/j.ijporl.2008.05.011

72. Decision Making in Medicine: An Algorithmic Approach. Mushlin SB, Greene HL, eds. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2009. 768 p. Available online: https://books.google.ru/books?id=kdBRlPlU3aUC&printsec=frontcover&hl=ru&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false. Accessed on: April 17, 2022.

73. Middleton PG, Wagenaar M, Matson AG, et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology. 2014;19(2):185-192. doi: https://doi.org/10.1111/resp.12227

74. Moran A, Pillay K, Becker DJ, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2014;15(Suppl. 20):65-76. doi: https://doi.org/10.1111/pedi.12178

75. Prentice B, Hameed S, Verge CF, et al. Diagnosing cystic fibrosis-related diabetes: current methods and challenges. Expert Rev Respir Med. 2016;10(7):799-811. doi: https://doi.org/10.1080/17476348.2016.1190646

76. Tangpricha V, Kelly A, Stephenson A, et al. An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97(4):1082-1093. doi: https://doi.org/10.1210/jc.2011-3050

77. Репина С.А., Красовский С.А., Роживанов Р.В. и др. Андрологическое обследование пациентов с легочной и смешанной формой муковисцидоза // Андрология и генитальная хирургия. — 2018. — Т. 19. — № 2. — С. 31-39. — doi: https://doi.org/10.17650/2070-9781-2018-19-2-31-39

78. Штаут М.И., Шилейко Л.В., Репина С.А. и др. Комплексное сперматологическое обследование пациентов с муковисцидозом // Андрология и генитальная хирургия. — 2017. — T. 18. — № 4. — С. 69-76. — doi: https://doi.org/10.17650/2070-9781-2017-18-4-69-76

79. Jungwirth A, Diemer T, Kopa Z, et al. EAU Guidelines on Male Infertility. European Association of Urology; 2018. 46 p. Available online: https://d56bochluxqnz.cloudfront.net/media/EAU-Guidelines-on-Male-Infertility-2018-large-text.pdf. Accessed on April 17, 2022.

80. Leifke E, Friemert M, Heilmann M, et al. Sex steroid sand body composition in men with cystic fibrosis. Eur J Endocrinol. 2003;148(5):551-557. doi: https://doi.org/10.1530/eje.0.1480551

81. Blackman SM, Tangpricha V. Endocrine Disordersin Cystic Fibrosis. Pediatr Clin North Am. 2016;63(4):699-708. doi: https://doi.org/10.1016/j.pcl.2016.04.009

82. Yoon JC, Casella JL, Litvin M, Dobs AS. Male reproductive health in cystic fibrosis. J Cyst Fibros. 2019;18(Suppl 2):S105-S110. doi: doi: https://doi.org/10.1016/j.jcf.2019.08.00718

83. Baatallah N, Bitam S, Martin N, et al. Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules. Hum Mutat. 2018;39(4):506-514. doi: https://doi.org/10.1002/humu.23389

84. Landsverk ML, Douglas GV, Tang S, et al. Diagnostic approaches to apparent homozygosity. Genet Med. 2012;14(10):877-882. doi: https://doi.org/10.1038/gim.2012.58

85. Hantash FM, Rebuyon A, Peng M, et al. Apparent homozygosity of a novel frame shift mutation in the CFTR gene because of a large deletion. J Mol Diagn. 2009;11(3):253-256. doi: https://doi.org/10.2353/jmoldx.2009.080117

86. Rechitsky S, Strom C, Verlinsky O, et al. Allele dropout in polar bodies and blastomeres. J Assist Reprod Genet. 1998;15(5):253-257. doi: https://doi.org/10.1023/a:1022532108472

87. Hantash FM, Redman JB, Goos D, et al. Characterization of a recurrent novel large duplication in the cystic fibrosis transmembrane conductance regulator gene. J Mol Diagn. 2007;9(4):556-560. doi: https://doi.org/10.2353/jmoldx.2007.060141

88. Hantash FM, Redman JB, Starn K, et al. Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening. Hum Genet. 2006;119(1-2):126-136. doi: https://doi.org/10.1007/s00439-005-0082-0

89. Dekkers JF, van der Ent CK, Beekman JM. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis. 2013;1:e27112. doi: https://doi.org/10.4161/rdis.27112

90. Boj SF, Vonk AM, Statia M, et al. Forskolin-induced swelling in intestinal organoids: an in vitro assay for assessing drug response in cystic fibrosis patients. J Vis Exp. 2017;(120):55159. doi: https://doi.org/10.3791/55159

91. Dekkers JF, Berkers G, Kruisselbrink E, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016;8(344):344ra384. doi: https://doi.org/10.1126/SCITRANSLMED.AAD8278

92. Vonk AM, van Mourik P, Ramalho AS, et al. Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. STAR Protoc. 2020;1(1):100019. doi: https://doi.org/10.1016/J.XPRO.2020.10001

93. Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther. 2019;13:2405-2412. doi: https://doi.org/10.2147/DDDT.S153719

94. Berkers G, van Mourik P, Vonk AM, et al. Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis. Cell Rep. 2019;26(7):1701-1708.e3. doi: https://doi.org/10.1016/j.celrep.2019.01.068

95. Southern KW, Patel S, Sinha IP, Nevitt SJ. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database Syst Rev. 2018;8(8):CD010966. doi: https://doi.org/10.1002/14651858.CD010966.pub2

96. Kolodziej M, de Veer MJ, Cholewa M, et al. Thompson Lung function imaging methods in Cystic Fibrosis pulmonary disease. Respir Res. 2017;18(1):96. doi: https://doi.org/10.1186/s12931-017-0578-x

97. Leutz-Shmidt P, Eichinger M, Stahl M, et al. Ten years of chest MRI for patients with cystic fibrosis: Translation from the bench to clinical routine. Radiologe. 2019;59(Suppl 1):10-20. doi: https://doi.org/10.1007/s00117-019-0553-2

98. Carter JM, Johnson BT, Patel A, et al. Lund-Mackay staging system in cystic fibrosis: a prognostic factor for revision surgery? The Ochsner J. 2014;14:184-187.

99. Kang SH, Dalcin PTR, Piltcher OB, Migliavacca RO. Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment. J Bras Pneumol. 2015;41(1):65-76. doi: https://doi.org/10.1590/S1806-37132015000100009

100. Детская хирургия: национальное руководство / под ред. Ю.Ф. Исакова, А.Ф. Дронова. — М.: ГЭОТАР-Медиа; 2009. — С. 328-331.

101. De Backer AI, De Schepper AM, Deprettere A, et al. Radiographic manifestations of intestinal obstruction in the newborn. JBR-BTR. 1999;82(4):159-166.

102. Sermet-Gaudelus I, Bianchi ML, Garabedian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011;10(2):S16-S23. doi: https://doi.org/10.1016/S1569-1993(11)60004-0

103. Bone mineralisation in cystic fibrosis: Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bromley: Cystic Fibrosis Trust; 2007. Available online: https://www.sifc.it/wp-content/uploads/2020/09/LineeGuidaSifc_Febbraio2007_BoneMineralisationInCF_UK_CFTrust_1.pdf. Accessed on April 17, 2022.

104. Скрипникова И.А., Щеплягина Л.А., Новиков В.Е. и др. Возможности костной рентгеновской денситометрии в клинической практике: методические рекомендации. — 2-е изд., доп. — М.; 2015.

105. Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society Standards of Care Committee British Thoracic Society guidelines for home oxygen use in adults. Thorax. 2015;70(Suppl 1):i1-i43. doi: https://doi.org/10.1136/thoraxjnl-2015-206865

106. Hayes D Jr, Wilson K, Krivchenia K, et al. Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;199(3):e5-e23. doi: https://doi.org/10.1164/rccm.201812-2276ST

107. Lam S, Nettel-Aguirre A, Van Biervliet S, et al. Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol. 2019;2(2):71-80. doi: https://doi.org/10.1093/jcag/gwy029

108. Jungwirth A, Giwercman A, Tournaye H, et al. European Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol. 2012;62(2):324-332. doi: https://doi.org/10.1016/j.eururo.2012.04.048

109. Zivanovic S, Saranac L, Kostic G. The case of pseudo-Bartter's syndrome: an atypical presentation of cystic fibrosis. Facta universitatis Series Medicine and biology. 2008;15(1):33-36.

110. Franco LP, Camargos PA, Becker HM, Guimaraes RE. Nasal endoscopic evaluation of children and adolescents with cystic fibrosis. Braz J Otorhinolaryngol. 2009;75(6):806-813. doi: https://doi.org/10.1016/s1808-8694(15)30541-3

111. Поляков Д.П., Карнеева О.В., Белавина П.И. Хронический риносинусит у детей с муковисцидозом: современные тенденции и собственный опыт // Российская ринология. — 2018. — Т. 26. — № 4. — С. 17-25. — doi: https://doi.org/10.17116/rosrino20182604117

112. Okafor S, Kelly KM, Halderman AA. Management of Sinusitis in the Cystic Fibrosis Patient. Immunol Allergy Clin North Am. 2020;40(2):371-383. doi: https://doi.org/10.1016/j.iac.2019.12.008

113. Hug MJ, Derichs N, Bronsveld I, Clancy JP. Measurement of ion transport function in rectal biopsies. Methods Mol Biol. 2011;741:87-107. doi: https://doi.org/10.1007/978-1-61779-117-8_7

114. Zommer-van Ommen DD, de Poel E, Krusselbrink E, et al. Comparison of Ex Vivo and in Vitro Intestinal Cystic Fibrosis Models to measure CFTR-dependent Ion Chanel Activity. J Cyst Fibros. 2018;17(3):316-324. doi: https://doi.org/10.1016/j.jcf.2018.02.007

115. Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediat Surg. 2012;47(4):772-781. doi: https://doi.org/10.1016/j.jpedsurg.2012.02.019

116. Munck A, Alberti C, Colombo C, et al. International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. J Cyst Fibros. 2016;15(4):531-539. doi: https://doi.org/10.1016/j.jcf.2016.02.002

117. Sandy NS, Massabki LHP, Goncalves AC, et al. Distal intestinal obstruction syndrome: a diagnostic and therapeutic challenge in cystic fibrosis. J Pediatr (Rio J). 2020;96(6):732-740. doi: https://doi.org/10.1016/j.jped.2019.08.009

118. Canny JD, Brookes A, Bowley DB. Distal intestinal obstruction syndrome and colonic pathologies in cystic fibrosis. Br J Hosp Med (Lond). 2017;78(1):38-43. doi: https://doi.org/10.12968/hmed.2017.78.1.38

119. Alattar Z, Thornley C, Behbahaninia M, Sisley A. Proximal small bowel obstruction in a patient with cystic fibrosis: a case report. Surg Case Rep. 2019;5(1):143. doi: https://doi.org/10.1186/s40792-019-0701-y

120. Abicht T, Jones C, Coyan G, et al. A technique for the surgical treatment of distal intestinal obstructive syndrome by hand-assisted laparoscopy. Surg Laparosc Endosc Percutan Tech. 2012;22(3):e142-e143. doi: https://doi.org/10.1097/SLE.0b013e318248b463

121. Martins LM, Camargos PA, Becker HM, et al. Guimaraes. Hearing loss in cystic fibrosis. Int J Pediat Otorhinolaryngol. 2010;74(5):469-473. doi: https://doi.org/10.1016/j.ijporl.2010.01.021

122. ENT complications. In: Clinical Guidelines: Care of children with cystic fibrosis. Royal Brompton Hospital; 2017. 7th ed. pp. 149-1521. Available online: https://www.rbht.nhs.uk/sites/nhs/files/Cystic%20fibrosis%20guidelines/CF%20guideline%202017%20FINAL%20-%2013%201%2017.pdf. Accessed on April 17, 2022.

123. Kreicher KL, Bauschard MJ, Clemmens CS, et al. Audiometric Assessment of Pediatric Patients With Cystic Fibrosis. J Cyst Fibros. 2018;17(3):383-390. doi: https://doi.org/10.1016/j.jcf.2017.10.007

124. Репина С.А., Красовский С.А., Сорокина Т.М. и др. Патогенный вариант 3849+10kbC>T гена CFTR как главный предиктор сохранения фертильности у мужчин с муковисцидозом // Генетика. — 2019. — Т. 55. — № 12. — C. 1481-1486. — doi: https://doi.org/10.1134/S0016675819120105

125. Хирургические болезни недоношенных детей: национальное руководство / под ред. Ю.А. Козлова, В.А. Новожилова, А.Ю. Разумовского. — М.: ГЭОТАР-Медиа; 2019. — С. 329-393.

126. Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(9):CD001127. doi: https://doi.org/10.1002/14651858.CD001127.pub4

127. Casale M, Vella P, Moffa A, et al. Hyaluronic acid and upper airway inflammation in pediatric population: a systematic review. Int J Pediatr Otorhinolaryngol. 2016;85:22-26. doi: https://doi.org/10.1016/j.ijporl.2016.03.015

128. Wark P, McDonald VM Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(9):CD001506. doi: https://doi.org/10.1002/14651858.CD001506.pub4

129. Nevitt SJ, Thornton J, Murray CS, Dwyer T. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. 2020;5(5):CD008649. doi: https://doi.org/10.1002/14651858.CD008649.pub4

130. Ziebach R, Pietsch-Breitfeld B, Bichler M, et al. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol. 2001;31(6):431-435. doi: https://doi.org/10.1002/ppul.1071

131. Avital A, Sanchez I, Chernick V. Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pulmonol. 1992;13(1):34-37. doi: https://doi.org/10.1002/ppul.1950130109

132. Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev.2017;12(12):CD012102. doi: https://doi.org/10.1002/14651858.CD012102.pub2

133. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;(4):CD003428. doi: https://doi.org/10.1002/14651858.CD003428.pub2

134. Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4): 286-291. doi: https://doi.org/10.1136/thx.2009.121657

135. Taccetti G, Bianchini E, Cariani L. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853-859. doi: https://doi.org/10.1136/thoraxjnl-2011-200832

136. Proesmans M, Vermeulen F, Boulanger L, et al. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013;12(1):29-34. doi: https://doi.org/10.1016/j.jcf.2012.06.001

137. Flume PA, Mogayzel PJ, Robinson KA. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. doi: https://doi.org/10.1164/rccm.200812-1845PP

138. McKinzie CJ, Chen L, Ehlert K, et al. Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2019;54(Suppl 3):S27-S45. doi: https://doi.org/10.1002/ppul.24511

139. Antibiotic treatment for cystic fibrosis: Report of the UK Cystic Fibrosis Trust Antibiotic Group. London: Cystic Fibrosis Trust; 2009. Available online: https://www.cysticfibrosis.org.uk/sites/default/files/2020-11/Anitbiotic%20Treatment.pdf. Accessed on April 17, 2022.

140. Solis A, Brown D, Hughes J. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol. 2003;36(3):189-195. doi: https://doi.org/10.1002/ppul.10231

141. Zobell JT, Epps KL, Young DC, et al. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol. 2015;50(6):552-559. doi: https://doi.org/10.1002/ppul.23132

142. Jennings MT, Boyle MP, Weaver D, et al. Eradication strategy for persistent methicillin-resistant infection in individuals with cystic fibrosis — the PMEP trial: study protocol for a randomized controlled trial. Trials. 2014;15:223. doi: https://doi.org/10.1186/1745-6215-15-223

143. Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med. 2018;18(1):20. doi: https://doi.org/10.1186/s12890-018-0588-6

144. Maiz L, Canton R, Mir N. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol. 1998;26(4):287-289. doi: https://doi.org/10.1002/(sici)1099-0496(199810)26:4<287::aid-ppul9>3.0.co;2-#

145. Weathers L, Riggs D, Santeiro M, Weibley RE. Aerosolized vancomycin for treatment of airway colonization by methicillin resistant Staphylococcus aureus. Pediatr Infect Dis J. 1990;9(3):220-221. doi: https://doi.org/10.1097/00006454-199003000-00017

146. Jennings MJ, Boyle MP, Bucur C, et al. Pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis. Pediatr Pulmonol. 2012;47(S35):320.

147. Boyle MP, Chmiel J. Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP). In: ClinicalTrials. gov. May 9, 2012. Available online: http://clinicaltrials.Gov/ct2/show/nct01594827. Accessed on April 17, 2022.

148. Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections. Ann Am Thorac Soc. 2014;11(7):1120-1129. doi: https://doi.org/10.1513/AnnalsATS.201402-050AS

149. Doring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461-479. doi: https://doi.org/10.1016/j.jcf.2012.10.004

150. Garazzino S, Altieri E, Silvestro E, et al. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data. Front Pediatr. 2020;8:173. doi: https://doi.org/10.3389/fped.2020.00173

151. European Society of Clinical Microbiology and Infection Diseases. Rational for EUCAST clinical breakpoints. In: EUCAST. European Committee on Antimicrobial Susceptibility Testing. Version 1.0. pp. 1-16. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ceftolozane-tazobactam_Rationale_1.0_20200515_v1.pdf. Accessed on April 17, 2022.

152. Morton R, Doe S, Banya W, Simmond NJ. Clinical benefit of continuous nebulised Aztreonam Lysine for Inhalation (AZLI) in adults with cystic fibrosis — a retrospective cohort study. J Cyst Fibros. 2017;16(Suppl 1):S55.

153. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018;3(3):CD001021. doi: https://doi.org/10.1002/14651858.CD001021.pub3

154. WHO AnthroPlus for personal computers Manual: Software for assessing growth of the world's children and adolescents. Geneva: World Health Organization; 2009. Available online: http://www.who.int/growthref/tools/en. Accessed on April 17, 2022.

155. Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;4(4):CD009876. doi: https://doi.org/10.1002/14651858.CD009876.pub4

156. Frost F, Shaw M, Nazareth D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;6(6):CD013079. doi: https://doi.org/10.1002/14651858.CD013079.pub2

157. Weidmann A, Webb AK, Dodd ME, Jones AM. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros. 2008;7(5):409-411. doi: https://doi.org/10.1016/j.jcf.2008.02.005

158. Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36(1):99-110. doi: https://doi.org/10.1055/s-0034-1396929

159. Swenson CE, Sadikot RT. Achromobacter Respiratory Infections. Ann Am Troc Soc. 2015;12(2);252-258. doi: https://doi.org/10.1513/AnnalsATS.201406-288FR

160. Wang M, Ridderberg W, Hansen CR, et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros. 2013;12(6):638-643. doi: https://doi.org/10.1016/j.jcf.2013.04.013

161. Edwards BD, Greysson-Wong J, Somayaji R, et al. Forbes Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study. J Clin Microbiol. 2017;55(7):2074-2085. doi: https://doi.org/10.1128/JCM.02556-16

162. Dupont C, Jumas-Bilak E, Michon AL, et al. Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing. J Clin Microbiol. 2016;55(1):206-215. doi: https://doi.org/10.1128/JCM.01843-16

163. Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility testing of Mycobacteria, Nocardiae, and Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2011. Report No.: M24-A2.

164. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1-ii64. doi: https://doi.org/10.1136/thoraxjnl-2017-210927

165. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2015;71(Suppl 1):i1-i22 doi: https://doi.org/10.1136/thoraxjnl-2015-207360

166. Согласованные рекомендации Американского фонда кистозного фиброза (муковисцидоза) и Европейского общества кистозного фиброза по лечению микобактериоза у пациентов с кистозным фиброзом / peg. пер. Н.Ю. Каширская. — СПб.: Благотворительный фонд «Острова»; 2017. — 32 с.

167. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза. — М.-Тверь: ООО «Издательство «Триада», 2014. — 56 с.

168. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. doi: https://doi.org/10.1164/rccm.200604-571ST

169. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):828-834. doi: https://doi.org/10.1164/rccm.200207-678OC

170. Martiniano SL, Sontag MK, Daley CL, et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc. 2014;11(1):36-44. doi: https://doi.org/10.1513/AnnalsATS.201309-310OC

171. Козлова Я.И., Борзова Ю.В., Суслова И.Е. и др. Аспергиллез легких у больных муковисцидозом // Журнал инфектологии. — 2018. — Т 10. — № 2. — С. 48-54. — doi: https://doi.org/10.22625/2072-6732-2018-10-2-48-54

172. Proesmans M, Vermeulen F, Vreys M, De Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr. 2010;2010:376287. doi: https://doi.org/10.1155/2010/376287

173. Hayes D Jr, Murphy BS, Lynch JE, Feola DJ. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2010;45(11):1145-1148. doi: https://doi.org/10.1002/ppul.21300

174. Elphick HE, Southern KW Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;11:CD002204.

175. Ассоциация клинических фармакологов. Официальный ответ на письмо № А-3/2 от 06 марта 2018. — 14 марта 2018. — № 29-2018. [Association of Clinical Pharmacologists. Official response to letter No. A-3/2 dated March 06, 2018. March 14, 2018. No. 29-2018. (In Russ).] Available online: https://mukoviscidoz.org/doc/med_doc/otvet-farmakologov.pdf. Accessed on April 17, 2022.

176. Burks TF. 10.08.3.2.3. Pancreatic enzyme preparations. In: Comprehensive Toxicology. Elsevier, NY; 2010. Vol. 10. Available online: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fibrosing-colonopathy. Accessed on April 17, 2022.

177. Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2014;(10):CD008227. doi: https://doi.org/10.1002/14651858.CD008227.pub2

178. Meyer JH, Elashoff J, Porter-Fink V, et al. Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology. 1988;94(6):1315-1325. doi: https://doi.org/10.1016/0016-5085(88)90669-5

179. Mundlos S, Kuehnelt P, Adler G. Monitoring enzyme re-placement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test. Gut. 1990;31(11):1324-1328. doi: https://doi.org/10.1136/gut.31.11.1324

180. Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S70-S78. doi: https://doi.org/10.1016/j.jcf.2017.06.011

181. Brodsky J, Dougherty S, Ramkrishna M, et al. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34(2):292-295. doi: https://doi.org/10.2337/dc10-1604

182. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros. 2009;8(3):174-178. doi: https://doi.org/10.1016/j.jcf.2008.12.001

183. van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016;15(6):834-838. doi: https://doi.org/10.1016/j.jcf.2016.07.009

184. Cheng K, Ashby D, Smyth RL, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10(2):S29-S36. doi: http://doi.org/10.1016/S1569-1993(11)60006-4

185. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2016. — Т. 26. — № 4. — С. 71-102. — doi: https://doi.org/10.22416/1382-4376-2016-26-4-71-102

186. Marquette M., Haworth C.S. Bone health and disease in cystic fibrosis. Paediatr Respir Rev. 2016;20(Suppl):2-5. doi: https://doi.org/10.1016/j.prrv.2016.06.003

187. Zhekaite E, Kondratyeva E, Ilenkova N, et al. The model for determining risk groups for the development of vitamin D deficiency and prevention algorithm in children with cystic fibrosis using the multifactor dimensionality reduction method. J Cyst Fibros. 2021;20(S1):S34. doi: https://doi.org/10.1016/S1569-1993(21)01015-8

188. Жекайте Е.К. Изучение влияния генетических и экзогенных факторов на развитие дефицита витамина D у детей и подростков с муковисцидозом в возрастном аспекте. Вопросы профилактики: автореф. дис. ... канд. мед. наук. М.; 2020.

189. Баранов А.А., Намазова-Баранова Л.С., Симонова О.И. и др. Современные представления о диагностике и лечении детей с муковисцидозом // Педиатрическая фармакология. — 2015. — Т. 12. — №. 5. — С. 589-604. — doi: https://doi.org/10.15690/pf.v12i5.1462

190. Harvey R, Hannan S.A, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev. 2007;(3):CD006394. doi: https://doi.org/10.1002/14651858.CD006394.pub2

191. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):):1-12. doi: https://doi.org/10.4193/Rhino12.000.

192. Beer H, Southern KW, Swift AC. Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis. Cochrane Database Syst Rev. 2015;(6):CD008253. doi: https://doi.org/10.1002/14651858.CD008253.pub4

193. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med. 2001;163(2):540-577. doi: https://doi.org/10.1164/ajrccm.163.2.9906116

194. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation — a consensus conference report. Consensus conference. Chest. 1999;116(2):521-534. doi: https://doi.org/10.1378/chest.116.2.521

195. Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020;19(3):344-354. doi: https://doi.org/10.1016/j.jcf.2020.02.015

196. King CS, Brown AW, Aryal S, et al. Critical Care of the Adult Patient With Cystic Fibrosis. Chest. 2019;155(1):202-214. doi: https://doi.org/10.1016/j.chest.2018.07.025

197. Flume PA. Pneumothorax in cystic fibrosis. Curr Opin Pulm Med. 2011;17(4):220-225. doi: https://doi.org/10.1097/MCP.0b013e328345e1f8

198. Shinohara T, Tsuda M, Koyama N. Management of meconium-related ileus in very low-birthweight infants. Pediat Int. 2007;49: 641644. doi: https://doi.org/10.1111/j.1442-200X.2007.02457.x

199. Parikh NS, Ahlawat R, Ahlawat R. Meconium Ileus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK537008. Accessed on April 17, 2022.

200. Colombo C, Ellemunter H, Houwen R, et al. ECFS Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(Suppl 2):S24-S28. doi: https://doi.org/10.1016/S1569-1993(11)60005-2

201. Schauble AL, Bisaccia EK, Lee G, Nasr SZ. N-acetylcysteine for Management of Distal Intestinal Obstruction Syndrome. J Pediatr Pharmacol Ther. 2019;24(5):390-397. doi: https://doi.org/10.5863/1551-6776-24.5.390

202. Wu HX, Zhu M, Xiong XF, et al. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Adv Ther. 2019;36(2):451-461. doi: https://doi.org/10.1007/s12325-018-0860-4

203. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231. doi: https://doi.org/10.1056/NEJMoa1409547

204. Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al OPTIMIZE Study Group Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med. 2018;198(9):1177-1187. doi: https://doi.org/10.1164/rccm.201802-0215OC

205. Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(4):430-437. doi: https://doi.org/10.1164/rccm.201906-1206OC

206. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011;(12):CD002203. doi: https://doi.org/10.1002/14651858.CD002203.pub3

207. Pukhalsky AL, Shmarina GV, Kapranov NI, et al. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004;13(2):111-117. doi: https://doi.org/10.1080/09629350410001688495

208. Konstan MW, Schluchter MD, Storfer-Isser A, Davis PB. Use of ibuprofen for the treatment of airway in flammation in CF: an update. Pediatr Pulmonol. 2002;34(S24):164.

209. Schluchter MD, Konstan MW, Xue L, Davis PB. Relationship between high-dose ibuprofen use and rate of decline in FEV1 among young patients with mild lung disease in the CFF Registry. Pediatr Pulmonol. 2004;38(S27):322.

210. Lands LC, Stanojevic S. Oral non-steroidal antiinflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019;9(9):CD001505. doi: https://doi.org/10.1002/14651858.CD001505.pub5

211. Physiotherapy for People with Cystic Fibrosis: from Infant to Adult. 7th ed. IPG/CF; 2019. Available online: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/IPG%20CF_Blue%20Booklet_7th%20edition%202019.pdf. Accessed on April 30, 2022.

212. Руководство по клиническому питанию / под ред. В.М. Луфта. — 3-е изд., перераб. — СПб.: Арт-Экспресс; 2016. — 409 с.

213. Программа оптимизации вскармливания детей первого года жизни в Российской Федерации: методические рекомендации / ФГАУ «НМИЦ здоровья детей» Минздрава России. — М.; 2019. — C. 70-71.

214. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibrosis. 2002;1(2): 51-75. doi: https://doi.org/10.1016/S1569-1993(02)00032-2

215. Кондратьева Е.И., Максимычева Т.Ю., Портнов Н.М. и др. Первые результаты применения компьютерной программы «Мониторинг нутритивного статуса, рациона питания и ферментной терапии» // Вопросы детской диетологии. — 2016. — Т. 14. — № 6. — С. 5-12. — doi: https://doi.org/10.20953/1727-5784-2016-6-5-12

216. Кондратьева Е.И., Орлов А.В., Максимычева Т.Ю. и др. Возможности оптимизации ферментной терапии при муковисцидозе // Педиатрия. Журнал им Г.Н. Сперанского. — 2018. — Т. 97. — № 6. — С. 104-112. — doi: https://doi.org/10.24110/0031-403X-2018-97-6-104-112

217. Максимычева Т.Ю., Кондратьева Е.И., Сорвачёва Т.Н. Оценка и коррекция нутритивного статуса у детей с муковисцидозом // Вопросы практической педиатрии. — 2018. — Т. 13. — № 5. — С. 24-32. — doi: https://doi.org/10.20953/1817-7646-2018-5-24-32

218. Максимычева Т.Ю., Кондратьева Е.И., Сорвачёва Т.Н., Одинаева Н.Д. Опыт коррекции нутритивного статуса нутритивного статуса у детей с муковисцидозом с использованием компьютерных систем и средств сетевой коммуникации // Сибирское медицинское обозрение. — 2019. — № 4. — С. 67-73. — doi: https://doi.org/10.20333/2500136-2019-4-67-73

219. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298-306. doi: https://doi.org/10.1164/rccm.201002-0157OC

220. Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest. 2005;128(2):729-738. doi: https://doi.org/10.1378/chest.128.2.729

221. Hamilos DL. Nasal and sinus problems in cystic fibrosis patients. In: The Nose and Sinuses in Respiratory Disorders (ERS Monograph). Bachert C, Bourdin A, Chanez P, eds. Sheffield: European Respiratory Society; 2017. pp. 48-66. doi: https://doi.org/10.1183/2312508X.10009616

222. Moss RB, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Arch Otolaryngol Head Neck Surg. 1995;121(5):566-572. doi: https://doi.org/10.1001/archotol.1995.01890050058011

223. Keck T, Rozsasi A. Medium-term symptom outcomes after paranasal sinus surgery in children and young adults with cystic fibrosis. Laryngoscope. 2007;117:475-479. doi: https://doi.org/10.1097/MLG.0b013e31802d6e4f.

224. Liang J, Higgins TS, Ishman SL, et al. Surgical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2013;3(10):814-822. doi: https://doi.org/10.1002/alr.21190

225. Boczar M, Sawicka E, Zybert K, Meconium ileus in newborns with cystic fibrosis - results of treatment in the group of patients operated on in the years 2000-2014. Dev Period Med. 2015;19(1):32-40.

226. Yusen R, Edwards L, Dipchand A. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016;35(11):1170-1184. doi: https://doi.org/10.1016/j.healun.2016.09.001

227. Репина С.А., Красовский С.А., Шмарина Г.В. и др. Состояние репродуктивной системы и алгоритм решения вопроса деторождения у мужчин с муковисцидозом // Альманах клинической медицины. — 2019. — Т. 47. — № 1. — С. 26-37. doi: https://doi.org/10.18786/2072-0505-2019-47-001

228. Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients J Cyst Fibros. 2005;4(2):77-87. doi: https://doi.org/10.1016/j.jcf.2004.10.003

229. Муковисцидоз, хронические воспалительные болезни легких // МУ 3.3.1.1123-02. Мониторинг поствакцинальных осложнений и их профилактика: методические указания. — М.; 2002. — 44 с. — Ч. 9.6.5.

230. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А.Г. Чучалина, В.В. Яснецова. — 17-е изд., перераб. и доп. — М.: ООО «Видокс»; 2016. — С. 745-768.

231. Чучалин А.Г., Биличенко Т.И., Осипова Г.Л. и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению: клинические рекомендации // Пульмонология. — 2015. — № 2. — С. 1-19.

232. Зверев В.В., Костинов М.П., Магаршак О.О. и др. Руководство по клинической иммунологии в респираторной медицине / под ред. М.П. Костинова, А.Г. Чучалина. — 2-е изд. — М.: Группа МДВ; 2018. — 304 с.

233. Ежлова Е.Б., Мельникова А.А., Баранов А.А. и др. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Streptococcus pneumoniae: методические рекомендации // Вакцинация. — 2011. — № 2. — С. 36-47.

234. Pneumococcal: Chapter 25. In: The Green Book. 2013. Available online: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25. Accessed on April 17, 2022.

235. Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947. doi: https://doi.org/10.15585/mmwr.mm6434a4

236. Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database Syst Rev. 2014;(8):CD008865. doi: https://doi.org/10.1002/14651858.CD008865.pub3

237. Костинов М.П., Магаршак О.О., Полищук В.Б. и др. Вакцинация взрослых с бронхолегочной патологией: руководство для врачей / под ред. М.П. Костинова. — М.: Арт-студия «Созвездие»; 2013. — 112 с.

238. Рыжов А.А., Костинов М.П., Магаршак О.О. Применение вакцин против пневмококковой и гемофильной типа b инфекций у лиц с хронической патологией // Эпидемиология и вакцино-профилактика. — 2004. — № 6. — С. 24-27.

239. Ong EL. Bilton D, Abbott J. et al. Influenza vaccination in adults with cystic fibrosis. BMJ. 1991;303(6802):6557-6802. doi: https://doi.org/10.1136/bmj.303.6802.557

240. Gross PA, Denning CR, Gaerlan PF, et al. Annual influenza vaccination: immune response in patients over 10 years. Vaccine. 1996;14(13):1280-1284. doi: https://doi.org/10.1016/s0264-410x(96)00004-7

241. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;2014(3):CD001753. doi: https://doi.org/10.1002/14651858.CD001753.pub3

242. МР 3.3.1.0001-10. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Haemophilus influenzae типа b: методические рекомендации. — М.; 2010. — С. 10.

243. Haemophilus influenzae type b (Hib) Vaccination Position Paper — July 2013. Wkly Epidemiol Rec. 2013;88(39):413-428.

244. Cerquetti M, Giufre M. Why we need a vaccine for non-typeable Haemophilus influenzae. Hum Vaccin Immunother. 2016;12(9):2357-2361. doi: https://doi.org/10.1080/21645515.2016.1174354.

245. Баранов А.А., Брико Н.И., Горелов А.В. и др. Стратегии контроля ветряной оспы в России. Итоги Международного совещания Экспертного Совета по вопросам профилактики ветряной оспы (W.A.V.E) // Вопросы современной педиатрии. — 2010. — Т. 9. — № 3. — С. 5-12.

246. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К. и др. Иммунопрофилактика менингококковой инфекции у детей: методические рекомендации. 2-е изд., доп. М.:Педиатр; 2019. 36 с.

247. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К. и др. Вакцинопрофилактика ротавирусной инфекции: клинические рекомендации. — М.; 2017. — 24 с.

248. Баранов А.А., Намазова-Баранова Л.С., Давыдова И.В. и др. Иммунопрофилактика респираторно-синцитиальной вирусной инфекции у детей: федеральные клинические рекомендации. М.: ПедиатрЪ; 2016. 28 с.

249. Kua KP, Lee SWH. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Pharmacotherapy. 2017;37(6):755-769. doi: https://doi.org/10.1002/phar.1936